ANGIOTENSIN-II ANTAGONISTS DUP-753 AND TCV-116

Background: Acute blockade of the renin-angiotensin system with the parenterally active angiotensin II antagonist saralasin has been shown to effectively lower blood pressure in a large fraction of patients with essential hypertension and to improve haemodynamics in some patients with congestive heart failure. It is now possible to chronically antagonize angiotensin II at its receptor using non-peptide angiotensin II inhibitors such as losartan (DuP 753/MK-954) or TCV 116. Effect of non-peptide angiotensin II antagonists: When administered by mouth, DuP753 and TCV116 induce dose-dependent inhibition of the presser response to exogenous angiotensin II. This effect is closely related to circulating levels of the corresponding active metabolites E3174 and CV11974. Preliminary studies performed in hypertensive patients suggest that losartan lowers blood pressure to an equivalent extent to an angiotensin converting enzyme (ACE) inhibitor. Conclusions: Further investigation is required to show whether these new angiotensin II antagonists compounds compare favourably with ACE inhibitors.